Gregory Parker
Hematology & Oncology · Oklahoma City, OKNPI 1972544625
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.4% of the total across 78 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 13.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $989 and has fallen 96.6% since, to $34 in 2021. That places this record below the midpoint for hematology & oncology clinicians in OK, where the typical reported total is $2,658.
Across 78 payments — averaging $16.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$177
- AstraZeneca$94
- Merck$82
- Pfizer$72
- Exelixis Inc.$70
- E.r. Squibb & Sons, L.L.C.$70
- plus $718 from 20 others
What the payments were for
- Food & beverage$1,21394%
- Education$726%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 10 | $177 |
| AstraZeneca(2 entities) | 6 | $94 |
| Merck | 5 | $82 |
| Pfizer | 5 | $72 |
| Exelixis Inc. | 3 | $70 |
| E.r. Squibb & Sons, L.L.C. | 5 | $70 |
| Tesaro, Inc. | 3 | $67 |
| AbbVie(2 entities) | 4 | $65 |
| Astellas Pharma US Inc | 4 | $50 |
| Lilly USA, LLC | 3 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $46 |
| EMD Serono, Inc. | 3 | $43 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $42 |
| Daiichi Sankyo Inc. | 2 | $38 |
| Taiho Oncology, Inc. | 2 | $37 |
| Teva Pharmaceuticals USA, Inc. | 2 | $36 |
| Array Biopharma Inc | 2 | $34 |
| Sanofi | 2 | $33 |
| Genentech USA, Inc. | 2 | $33 |
| Bayer | 2 | $32 |
| Novocure Inc. | 1 | $24 |
| Karyopharm Therapeutics Inc. | 2 | $24 |
| Verastem, Inc. | 2 | $24 |
| Rigel Pharmaceuticals, Inc. | 1 | $17 |
| Seagen Inc. | 1 | $14 |
| Dendreon Pharmaceuticals LLC | 1 | $13 |
How this compares
$1,285 in reported general payments places this provider in the 30th percentile of 118 hematology & oncology providers in Oklahoma.
Other hematology & oncology in Oklahoma City
- Romeo MandanasOklahoma City$160K
- Mohammad RazaqOklahoma City$56K
- Sami IbrahimiOklahoma City$41K
- Jennifer Holter-ChakrabartyOklahoma City$39K
- Hassan HatoumOklahoma City$23K
- Abdul Rafeh NaqashOklahoma City$23K
- Taha Al-JuhaishiOklahoma City$23K
- Adanma Anji Ayanambakkam AttanathiOklahoma City$16K
- Robert ReynoldsOklahoma City$15K
- Sadia ChohanOklahoma City$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.